Current Report Filing (8-k)
December 19 2014 - 4:55PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT
TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): December 16, 2014
Kite Pharma, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
|
001-36508 |
|
27-1524986 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification No.) |
|
|
2225 Colorado Avenue
Santa Monica, California |
|
90404 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrants telephone number, including area code: (310) 824-9999
Not Applicable
(Former
name or former address, if changed since last report.)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
On December 15, 2014, the Compensation Committee (the Committee) of the
Board of Directors (the Board) of Kite Pharma, Inc. (Kite) reviewed Kites 2014 corporate goals and determined that on an overall basis, Kite had substantially achieved all of its goals. In recognition of Kites
achievement of substantially all of its 2014 corporate goals and each officers efforts towards successful achievement of such goals, the Committee recommended to the Board that each of the Kite officers receive 100% of their target bonus
opportunity for 2014 (prorated for any partial year of employment).
At 100% of the target bonus opportunity, the employed named executive officers Arie
Belldegrun, M.D., FACS, President and Chief Executive Officer, would receive $200,000, and Marc Better, Ph.D., Vice President, Product Science, would receive $84,000. In addition, Cynthia M. Butitta, Chief Operating Officer and Chief Financial
Officer, would receive $150,000.
Also, in recognition of extraordinary performance, the Committee recommended to the Board the payment of an additional
$100,000 performance bonus to Dr. Belldegrun and an additional $75,000 performance bonus to Ms. Butitta.
On December 16, 2014, based on
the Committees recommendation, the Board approved the payment of performance bonuses discussed above.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
Date: December 19, 2014 |
|
KITE PHARMA, INC.
(Registrant) |
|
|
|
|
|
By: |
|
/s/ Cynthia M. Butitta |
|
|
Name: |
|
Cynthia M. Butitta |
|
|
Title: |
|
Chief Financial Officer and Chief Operating Officer |
KITE PHARMA, INC. (NASDAQ:KITE)
Historical Stock Chart
From Mar 2024 to Apr 2024
KITE PHARMA, INC. (NASDAQ:KITE)
Historical Stock Chart
From Apr 2023 to Apr 2024